Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2020-05-29 Declaration of Voting R…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Ändring av antal aktier och röster i Abliva AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement (2622 characters) in Swedish titled "Ändring av antal aktier och röster i Abliva AB (publ)" (Change in the number of shares and votes in Abliva AB (publ)). It explicitly states that the number of shares and votes has increased due to the completion of a rights issue. It also mentions that this information is required to be made public according to financial instrument trading laws and is dated May 29, 2020. Crucially, the document includes a section titled "Bifogade filer" (Attached files) with a link to a PDF detailing the change. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of information or attaching a file, rather than being the full report itself, should be classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Since this is a specific regulatory update regarding share capital changes, it fits best under the category for announcements related to capital structure changes or general regulatory announcements. The core event is a change in the total number of shares following a financing activity (rights issue). This points towards 'Share Issue/Capital Change' (SHA) or a general regulatory announcement (RNS). Given the specific nature of announcing the final count after a capital action, SHA is highly relevant, but since it is presented as a brief press release announcing the result of a prior action, and often these specific capital change announcements are filed broadly, RNS is a safe fallback. However, the content directly relates to 'Share Issue/Capital Change' (SHA). Since it is a formal announcement of a change in the total number of shares, SHA is the most precise fit among the specific codes, even if it's short. If SHA is not deemed appropriate for a simple notification of the final count, RNS would be the fallback. Given the explicit mention of the increase in shares resulting from a rights issue, SHA is the primary classification.
2020-05-29 Swedish
Amended number of shares and votes in Abliva AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly announces an 'Amended number of shares and votes' following a preferential rights issue. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the core subject matter is a capital change, not just the announcement of a report (RPA/RNS). The text mentions the resolution dates (Feb 19, Mar 17) and the final share count (269,673,466), confirming it is the primary disclosure of the capital event.
2020-05-29 English
Beslut vid årsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document text is titled "Beslut vid årsstämma i NeuroVive Pharmaceutical AB (publ)" which translates to "Decisions at the Annual General Meeting (AGM) in NeuroVive Pharmaceutical AB (publ)". The content explicitly details the resolutions passed at the AGM held on May 20, 2020, covering the approval of financial statements, dividend decisions, election of the board and auditor, and approval of remuneration guidelines. This content directly corresponds to the purpose of an AGM resolution summary. Although it is a press release format, the core subject matter is the outcome of the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R).
2020-05-20 Swedish
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document explicitly states in the title and opening paragraph that it contains the "Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)" held on May 20, 2020. It details the outcomes of shareholder votes regarding the approval of financial statements, dividend policy, election of the Board, remuneration guidelines, and authorization for share issues. This content directly corresponds to the outcomes of an Annual General Meeting (AGM). Although it is a summary of resolutions, it is the primary output of the meeting itself, making 'AGM Information' (AGM-R) the most appropriate classification, rather than a proxy statement (PSI) or a general regulatory filing (RNS).
2020-05-20 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport januari-mars 2020' (Interim Report January-March 2020) for NeuroVive Pharmaceutical AB. It contains detailed financial information for the first quarter, including income statements, business highlights, and management commentary on projects and strategy. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2020
2020-05-20 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is titled 'NeuroVive Pharmaceutical AB (publ) Interim Report January-March 2020'. It contains comprehensive financial information for the first quarter, including net revenues, loss before tax, and loss per share, as well as detailed management commentary on business strategy, clinical trial progress, and the impact of COVID-19. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2020
2020-05-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.